

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 31/40	A1	(11) International Publication Number: WO 94/25023 (43) International Publication Date: 10 November 1994 (10.11.94)
<p>(21) International Application Number: PCT/IB94/00079</p> <p>(22) International Filing Date: 26 April 1994 (26.04.94)</p> <p>(30) Priority Data: 08/053,930 27 April 1993 (27.04.93) US</p> <p>(71) Applicant: PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US).</p> <p>(72) Inventor: MACOR, John, Eugene; 83 Corrina Lane, Salem, CT 06420 (US).</p> <p>(74) Agents: SPIEGEL, Allen, J. et al.; Pfizer Inc., 235 East 42nd Street, New York, NY 10017 (US).</p>		<p>(81) Designated States: AU, BG, BR, CA, CN, CZ, FI, HU, JP, KR, NO, NZ, PL, RO, RU, SK, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p>
<p>(54) Title: USE OF INDOLE DERIVATIVES AS 5HT1 ANTAGONISTS</p> <p>(57) Abstract</p> <p>The present invention relates to pharmaceutical compositions and methods of use of 5-(Methylaminosulfonylmethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole and 5-(Methylaminosulfonylmethyl)-3-(pyrrolidin-2-ylmethyl)-1H-indole.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

-1-

Use of indole derivatives as 5HT₁ antagonists

5

Background of the Invention

The present invention relates to pharmaceutical compositions containing indole derivatives and to their medicinal use. The active compounds of the present invention are useful in treating migraine and other disorders.

United States Patents 4,839,377 and 4,855,314 and European Patent Application Publication Number 313397 refer to 5-substituted 3-aminoalkyl indoles. The compounds are said to be useful for the treatment of migraine.

British Patent Application 040279 refers to 3-aminoalkyl-1H-indole-5-thioamides and carboxamides. The compounds are said to be useful in treating hypertension, Raymond's disease and migraine.

European Patent Application Publication Number 303506 refers to 3-poly:hydro-pyridyl-5-substituted-1H-indoles. The compounds are said to have 5HT₁-receptor agonist and vasoconstrictor activity and to be useful in treating migraine.

European Patent Application Publication Number 354777 refers to N-piperidinyl:indolyl:ethyl-alkane sulfonamide derivatives. The compounds are said to have 5HT₁-receptor agonist and vasoconstrictor activity and to be useful in treating cephalic pain.

The compounds are generically disclosed in International Publication. No. WO 92/06973.

Summary of the Invention

The present invention relates to pharmaceutical compositions and methods of use of (R)-5-(methylaminosulfonylmethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole and (R)-5-(methylaminosulfonylmethyl)-3-(pyrrolidin-2-ylmethyl)-1H-indole (hereinafter also referred to as the active indoles).

The present invention relates to a pharmaceutical composition for treating a condition selected from

-2-

hypertension, depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain, and chronic paroxysmal hemicrania and headache associated with vascular disorders comprising an amount of a compound of the
5 active indoles or a pharmaceutically acceptable salt thereof effective in treating such condition and a pharmaceutically acceptable carrier.

The present invention also relates to a pharmaceutical composition for treating disorders arising from deficient
10 serotonergic neurotransmission (e.g., depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain, and chronic paroxysmal hemicrania and headache associated with vascular disorders) comprising an amount of a compound of the active indoles or a
15 pharmaceutically acceptable salt thereof effective in treating such condition and a pharmaceutically acceptable carrier.

The present invention also relates to a method for treating a condition selected from hypertension, depression,
20 anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain and chronic paroxysmal hemicrania and headache associated with vascular disorders.

The present invention also relates to a method for treating disorders arising from deficient serotonergic
25 neurotransmission.

Detailed Description of the Invention

The active indoles used in the present invention can be prepared using the methods disclosed in International Publication No. WO 92/06973.

30 The active indoles are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate an active indoles
35 from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free

-3-

base compound by treatment with an alkaline reagent, and subsequently convert the free base to a pharmaceutically acceptable acid addition salt. The acid addition salts of the active indoles are readily prepared by treating the compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is obtained.

10 The acids which are used to prepare the pharmaceutically acceptable acid addition salts of the active indoles are those which form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as hydrochloride, hydrobromide, hydroiodide, 15 nitrate, sulfate or bisulfate, phosphate or acid phosphate, acetate, lactate, citrate or acid citrate, tartrate or bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate and pamoate [i.e., 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)] salts.

20 The active indoles and the pharmaceutically acceptable salts thereof (hereinafter, also referred to as the active compounds) are useful psychotherapeutics and are potent serotonin (5-HT₁) agonists and may be used in the treatment of depression, anxiety, eating disorders, obesity, drug 25 abuse, cluster headache, migraine, chronic paroxysmal hemicrania and headache associated with vascular disorders, pain, and other disorders arising from deficient serotonergic neurotransmission. The compounds can also be used as centrally acting antihypertensives and vasodilators.

30 The active compounds of the invention are evaluated as anti-migraine agents by testing the extent to which they mimic sumatriptan in contracting the dog isolated saphenous vein strip (P.P.A. Humphrey et al., Br. J. Pharmacol., 94, 1128 (1988)). This effect can be blocked by methiothepin, 35 a known serotonin antagonist. Sumatriptan is known to be useful in the treatment of migraine and produces a selective

-4-

increase in carotid vascular resistance in the anaesthetized dog. It has been suggested (W. Fenwick et al., Br. J. Pharmacol., 96, 83 (1989)) that this is the basis of its efficacy.

5 The active compounds of the present invention are also evaluated as anti-migraine agents via the inhibition of plasma protein extravasation response within the dura mater of guinea pigs following unilateral electrical trigeminal ganglion stimulation. The extent to which they mimic
10 sumatriptan, in terms of both potency and efficacy, is determined in this assay. The procedure is performed on male Hartley guinea pigs (200-250 g, Charles River Laboratories, Wilmington, MA, U.S.A.) as described in Markowitz et al., J. Neurosci., 7 (12), 4129-4136 (1987) and
15 also in Lee, et al., Brain Reseach, 626, 303-305 (1993). The procedure briefly consists of placing pentobarbitone-anesthetized animals in a stereotaxic frame. ¹²⁵I-BSA (bovine serum albumin) (50 μ Ci/kg⁻¹) is first injected into the femoral vein, followed 5 minutes later by drug or vehicle.
20 Bipolar electrodes are then lowered into the trigeminal ganglia, and the right ganglion is stimulated for 5 minutes (1.2 nA, 5 Hz, 5 msec). The animal is then perfused with saline through the left cardiac ventricle and sacrificed, and the dura mater is dissected, weighed, and counted for
25 radioactivity. Cpm/mg wet weight values are determined for the right vs left dura mater, and a ratio for the stimulated vs unstimulated sides is generated for each animal. Unpaired student's t-test is used to statistically compare these ratio values in respective groups treated with vehicle
30 or drug. The M.E.D. (minimally effective dose) for a given compound is the lowest dose for which the mean value of this ratio is significantly lower than that obtained for the vehicle-treated group. The effect of the drugs in these assays can be partially blocked by metergoline, a known
35 serotonin antagonist.

-5-

The compositions of the present invention may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers. Thus, the active compounds of the invention may be formulated for oral, buccal, intranasal, parenteral (e.g., intravenous, intramuscular or subcutaneous) or rectal administration or in a form suitable for administration by inhalation or insufflation.

For oral administration, the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium starch glycollate); or wetting agents (e.g. sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g. sorbitol syrup, methyl cellulose or hydrogenated edible fats); emulsifying agents (e.g. lecithin or acacia); non-aqueous vehicles (e.g. almond oil, oily esters or ethyl alcohol); and preservatives (e.g. methyl or propyl p-hydroxybenzoates or sorbic acid).

For buccal administration the composition may take the form of tablets or lozenges formulated in conventional manner.

The active compounds of the invention may be formulated for parenteral administration by injection, including using conventional catheterization techniques or infusion.

-6-

Formulations for injection may be presented in unit dosage form e.g. in ampules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulating agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for reconstitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.

10 The active compounds of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.

For intranasal administration or administration by inhalation, the active compounds of the invention are conveniently delivered in the form of a solution or suspension from a pump spray container that is squeezed or pumped by the patient or as an aerosol spray presentation from a pressurized container or a nebulizer, with the use of a suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. The pressurized container or nebulizer may contain a solution or suspension of the active compound. Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.

30 A proposed dose of the compound (R)-5-(methylaminosulfonylmethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole for oral, parenteral or buccal administration to the average adult human for the treatment of the conditions referred to above (e.g., migraine) is 0.1 μ g to 200 mg of the active ingredient per unit dose which

-7-

could be administered, for example, 1 to 4 times per day. In one embodiment, the pharmaceutical composition includes 0.1 μg to less than 0.1 mg of the active ingredient per unit dose, in another embodiment, the pharmaceutical composition includes 0.1 μg to 0.09 mg of the active ingredient per unit dose, and in still another embodiment, the pharmaceutical composition includes 0.5 μg to 0.09 mg of the active ingredient per unit dose.

A proposed dose of the compound (R)-5-(methylaminosulfonylmethyl)-3-(pyrrolidin-2-ylmethyl)-1H-indole for oral, parenteral or buccal administration to the average adult human for the treatment of the conditions referred to above (e.g., migraine) is 0.01 μg to 200 mg of the active ingredient per unit dose which could be administered, for example, 1 to 4 times per day. In one embodiment, the pharmaceutical composition includes 0.01 μg to less than 0.1 mg of the active ingredient per unit dose, in another embodiment, the pharmaceutical composition includes 0.01 μg to 0.09 mg of the active ingredient per unit dose, and in still another embodiment, the pharmaceutical composition includes 0.05 μg to 0.09 mg of the active ingredient per unit dose.

Aerosol formulations for treatment of the conditions referred to above (e.g., migraine) in the average adult human are preferably arranged so that each metered dose or "puff" of aerosol contains 0.01 μg to 1000 μg of either of the compounds (R)-5-(methylaminosulfonylmethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole or (R)-5-(methylaminosulfonylmethyl)-3-(pyrrolidin-2-ylmethyl)-1H-indole. In one embodiment, each metered dose or "puff" of aerosol contains 0.01 μg to less than 20 μg of the active ingredient, in another embodiment, each metered dose or "puff" of aerosol contains 0.01 μg to 19 μg of the active ingredient, and in still another embodiment, each metered dose or "puff" of aerosol contains 0.05 μg to 19 μg of the active ingredient. The overall daily dose with an aerosol

-8-

will be within the range 0.05 μ g to 10 mg. In one embodiment, the overall daily dose with an aerosol will be within the range 0.05 μ g to less than 100 μ g of the active ingredient, and in another embodiment, the overall daily dose with an aerosol will be within the range 0.05 μ g to 99 μ g of the active ingredient. Administration may be several times daily, for example 2, 3, 4 or 8 times, giving for example, 1, 2 or 3 doses each time.

The following Examples illustrate the preparation of the compounds of the present invention. Melting points are uncorrected. NMR data are reported in parts per million (δ) and are referenced to the deuterium lock signal from the sample solvent. Specific rotations were measured at room temperature using the sodium D line (589 nm).

Commercial reagents were utilized without further purification. Chromatography refers to column chromatography performed using 32-63 μ m silica gel and executed under nitrogen pressure (flash chromatography) conditions. Room temperature refers to 20 - 25°C.

EXAMPLE 1

(R)-5-(Methylaminosulfonylmethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole

To a stirred mixture of lithium aluminum hydride (0.221 g, 5.82 mmol, 2 eg) in anhydrous tetrahydrofuran (15 mL) at 0°C was added rapidly a solution of (R)-3-(N-Benzyloxycarbonylpyrrolidin-2-ylmethyl)-5-(methylaminosulfonylmethyl)-1H-indole (2.97 mmol) in anhydrous tetrahydrofuran (5 mL). The resulting mixture was heated at reflux under a nitrogen atmosphere for 3 hours. The reaction mixture was cooled, and sodium sulfate decahydrate (5g) and water (0.5 mL) were added. The resulting mixture was stirred at 25°C for 8 hours, filtered, and the filtrate was evaporated under reduced pressure. The residue was column chromatographed using silica gel (approximately 50 g) and elution with a solution methylene chloride: methanol: ammonium hydroxide [9:1:0.1] to afford

-9-

the title compound as a white solid (340 mg, 78%): mp, 213.0-214.0°C; ¹H NMR (DMSO-d₆) δ 10.9 (br s, indole NH), 7.51 (br d, 1H), 7.31 (d, *J*=8.3 Hz, 1H), 7.16 (br d, 1H), 7.08 (br dd, *J*=8.3 Hz, 1H), 6.82 (br q, sulfonamide NH), 4.35 (s, 2H), 3.07-2.95 (m, 2H), 2.54 (d, *J*=4.7 Hz, 3H), 2.52-2.38 (m, 2H), 2.35 (s, 3H), 2.10 (br, q, *J*=8.2 Hz, 1H), 1.75-1.40 (m, 4H); [α]²⁵=+89° (DMSO-d₆, c=1.0); Anal. calcd for C₁₆H₂₃N₃SO₂: C, 59.79; H, 7.21; N, 13.07. Found: C, 59.66; H, 7.29; N, 12.81.

10

EXAMPLE 2(R)-5-(Methylaminosulfonylmethyl)-3-(pyrrolidin-2-ylmethyl)-1H-indole

A mixture of (R)-3-(N-Benzyloxycarbonylpyrrolidin-2-ylmethyl)-5-(methylaminosulfonylmethyl)-1H-indole (0.62 g, 1.40 mmol) and 20% Pd(OH)₂ on carbon (0.63 g) in absolute ethanol was shaken under a hydrogen atmosphere (3 atm) for 16 hours. The resulting reaction mixture was filtered through diatomaceous earth, and the filtrate was evaporated under reduced pressure. The residue was column chromatographed using silica gel (approximately 50 g) and elution with a solution of methylene chloride: methanol: ammonium hydroxide [8:2:0.2] to afford the title compound (0.216 g, 44%) as an off-white gum: ¹³C NMR (DMSO-d₆) δ 135.9, 127.5, 123.8, 123.7, 120.9, 119.7, 112.4, 111.1, 59.2, 56.6, 45.7, 31.1, 31.0, 29.0, 24.6; [α]²⁵ = +4° (DMSO-d₆, c=1.0); [α]²⁵=-14° (EtOH/CHCl₃, [1:1], c=1.0); HRMS: calculated for [C₁₅H₂₁N₃O₂S•H⁺]: 308.1433; found: 308.1467.

20

25

EXAMPLE 3(R)-3-(N-Benzyloxycarbonylpyrrolidin-2-ylmethyl)-5-(methylaminosulfonylmethyl)-1H-indole

30

A mixture of (R)-1-(N-Benzyloxycarbonylpyrrolidin-2-yl)-3-(N-(2-bromo-4-methylaminosulfonylmethylphenyl)-N-trifluoroacetyl)propene (4.00 g, 6.47 mmol), tetrabutylammonium chloride (1.84 g, 6.62 mmol), and palladium(II) acetate (.407 g, 1.82 mmol, 0.3 eq) in a solution of triethylamine (22 mL) and anhydrous N,N-

35

-10-

dimethylformamide (5 mL) was heated at reflux under nitrogen for 1 hour. The resulting reaction mixture was evaporated under reduced pressure, and the residue was partitioned between ethyl acetate (100 mL) and water (100 mL). The ethyl acetate layer was removed, and the aqueous layer was extracted with additional ethyl acetate (100 mL). The organic extracts were combined, dried (MgSO_4), and evaporated under reduced pressure. The residue was column chromatographed using silica gel (approximately 400 g) and elution with an acetone gradient (0.5%-5%) in methylene chloride to afford the title compound (1.30 g, 45%) as an off-white foam: IR (CHCl_3) 1673, 1410, 1358, 1324, 1118, 1092 cm^{-1} ; LRMS (m/z , relative intensity) 441 (9, M^+), 237 (29), 204 (77), 160 (97), 143 (73), 91 (100); HRMS: calculated for $\text{C}_{23}\text{H}_{27}\text{N}_3\text{O}_4\text{S}$: 441.1724; found: 441.1704; $[\alpha]^{25} = -30^\circ$ (CD_3OD , $\text{C}=1$).

EXAMPLE 4

(R)-1-(N-Benzylloxycarbonylpyrrolidin-2-yl)-3-(N-(2-bromo-4-methylaminosulfonylmethylphenyl)-N-trifluoroacetyl amino)propene

To a stirred mixture of (R)-1-(N-benzylloxycarbonylpyrrolidin-2-yl)-3-hydroxypropene (3.75 g, 14.3 mmol), 2-bromo-4-methylaminosulfonylmethyl-N-trifluoroacetylaniline (4.45 g, 11.8 mmol) and triphenylphosphine (3.78 g, 14.4 mmol) in anhydrous tetrahydrofuran (60 mL) at 0°C under a nitrogen atmosphere was added diethyl azodicarboxylate (2.30 mL, 14.1 mmol) dropwise. The reaction solution was slowly warmed to 25°C over the course of 2 hours, and then stirred at 25°C under a nitrogen atmosphere for an additional 12 hours. The resulting reaction solution was evaporated under reduced pressure, and the residue was column chromatographed using silica gel (approximately 600 g) and elution with 4% acetone in methylene chloride afforded the title compound as a white foam (4.06 g, 46%): FAB LRMS (m/z , relative intensity) 620 ($[\text{MH}^+$ with ^{81}Br], 618 ($[\text{MH}^+$ with ^{79}Br], 98),

-11-

576 (50), 574 (63), 512 (17), 484 (33); $[\alpha]^{25} = +18\%$ (CH₃OH, C=1).

EXAMPLE 5

5 2-Bromo-4-methylaminosulfonylmethyl-N-trifluoroacetyl-aniline

To a stirred solution of 2-Bromo-4-methylaminosulfonylmethylaniline (0.55 g, 2.00 mmol) and pyridine (0.18 mL, 2.22 mmol, 1.1 eq) in anhydrous methylene chloride (10 mL) at 0°C under a nitrogen atmosphere was
10 added dropwise trifluoroacetic anhydride (0.31 mL, 2.19 mmol, 1.1 eq). The resultant reaction mixture was stirred at 0°C under a nitrogen atmosphere for 3 hours. A saturated solution of sodium hydrogen carbonate was added (15 mL), and this aqueous mixture was extracted with ethyl acetate (3 x
15 15 mL). The extracts were combined, dried (MgSO₄), and evaporated under reduced pressure. Evaporation of the ethyl acetate extracts afforded the title compound (0.675 g, 90%) directly as a white solid: mp, 164.0-166.0°C. Anal. calcd for C₁₀H₁₀BrF₃N₂O₃S: C, 32.02; H, 2.69; N, 7.47. Found: C,
20 32.18; H, 2.67; N, 7.30.

EXAMPLE 6

2-Bromo-4-methylaminosulfonylmethylaniline

To a stirred solution of 4-Methylaminosulfonylmethylaniline (M.D. Dowle, et al. Eur.
25 Pat. Appl. EP225,726) (0.40 g, 2.00 mmol) in methanol (10 mL) at 0°C was added dropwise bromine (0.113 mL, 2.19 mmol, 1.1 eq). The resulting reaction mixture was then stirred at 25°C for 30 minutes. The reaction mixture was then evaporated under reduced pressure, and the residue was
30 placed in a saturated solution of sodium hydrogen carbonate (10 mL). This aqueous mixture was extracted with ethyl acetate (3 x 15 mL). The extracts were combined, dried (MgSO₄), and evaporated under reduced pressure. The residue was column chromatographed using silica gel (approximately
35 50 g) and elution with 40% ethyl acetate in hexanes afforded the title compound (0.145 g, 26%) as a white solid: mp,

-12-

104.0-107.0°C. Anal. calcd for $C_8H_{11}BrN_2O_2S$: C, 34.42; H, 3.97; N, 10.04. Found: C, 34.66; H, 3.96; N, 9.96.

EXAMPLE 7

5 (R)-1-(N-Benzylloxycarbonylpyrrolidin-2-yl)-3-hydroxypropene

To a stirred solution of (R)-ethyl 3-(N-benzylloxycarbonylpyrrolidin-2-yl)-2-propenoate (3.03 g, 10.00 mmol) in anhydrous tetrahydrofuran (75 mL) at -78°C under nitrogen was added dropwise a solution of
10 diisobutylaluminium hydride (1.0 M in hexanes, 12.0 mL, 22.0 mmol, 2.2 eq). The resulting solution was stirred at -78°C under nitrogen for 30 minutes. The reaction solution was then allowed to warmed to room temperature over the course of 2 hours. A saturated solution of sodium hydrogen
15 carbonate (50 mL) was added, and the aqueous mixture was extracted with ethyl acetate (3 x 50 mL). The extracts were combined, dried ($MgSO_4$), and evaporated under reduced pressure. Column chromatography of the residue with diethyl ether/hexanes [1:1] afforded the title compound (0.836 g,
20 32%) as a clear, colorless oil: 1H NMR ($CDCl_3$) δ 7.40-7.25 (m, 5H), 5.75-5.53 (m, 2H), 5.20-5.00 (m, 2H), 4.38 (br m, 1H), 4.06 (br d, $J=13.7$ Hz, 2H), 3.45 (br t, $J=7.0$ Hz, 1H), 2.03-1.68 (m, 4H); $[\alpha]^{25} = +34^\circ$ (MeOH, $c=1.0$); HRMS: calculated for $C_{15}H_{19}NO_3$, 261.1365, found 261.1356.

25

EXAMPLE 8

(R)-Ethyl 3-(N-Benzylloxycarbonylpyrrolidin-2-yl)-2-propenoate

To a stirred solution of (R)-N-carbobenzylloxypyrrolidine-2-carboxaldehyde (1.17 g, 5.00
30 mmol) [S. Kiyooka, et al., J. Org. Chem., 5409 (1989) and Y. Hamada, et al., Chem. Pharm. Bull., 1921 (1982)] in anhydrous tetrahydrofuran at -78°C was added (carbethoxymethylene)triphenylphosphorane (2.09 g, 6.00 mmol, 1.2 eq) as a solid portionwise. The resulting
35 reaction mixture was stirred at room temperature under nitrogen for 2 hours. The reaction mixture was evaporated

-13-

under reduced pressure and the residue was column chromatographed using silica gel (approximately 100 g) and elution with 20% diethyl ether in hexanes to afford the title compound (1.26 g, 83%) as a clear, colorless oil: ¹H NMR (CDCl₃-d₆) δ 7.34-7.25 (m, 5H), 6.89-6.76 (m, 1H), 5.88-5.74 (m, 1H), 5.18-5.05 (m, 2H), 4.60-4.43 (m, 1H), 4.17 (q, J=7.1 Hz, 2H), 3.55-3.40 (m, 2H), 2.11-2.00 (m, 1H), 1.90-1.75 (m, 3H), 1.28 (t, J=7.1 Hz, 3H); ¹³C NMR (CDCl₃) [Note: due to slow nitrogen inversion two conformers of the products are seen by NMR spectroscopy] δ 166.3, 154.7, 147.9, 147.4, 136.6, 128.4, 127.9, 120.9, 66.9, 65.8, 60.4, 58.1, 57.7, 46.8, 46.4, 31.6, 30.8, 23.6, 22.8, 22.6, 15.3, 14.2; [α]_D²⁵=+61° (CH₃OH, C=1).

EXAMPLE 9

In vivo Assay of Plasma Protein Extravasation Response within The Dura Mater of Guinea Pigs

The procedure described previously in this application referencing Markowitz et al., J. Neurosci., 7 (12), 4129-4136 (1987) and in Lee, et al., Brain Research, 626, 303-305 (1993) was performed on (R)-5-(Methylaminosulfonylmethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole and (R)-5-(Methylaminosulfonylmethyl)-3-(pyrrolidin-2-ylmethyl)-1H-indole. The results for (R)-5-(Methylaminosulfonylmethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole was an ED₅₀=1.66 pmol/kg. The results for (R)-5-(Methylaminosulfonylmethyl)-3-(pyrrolidin-2-ylmethyl)-1H-indole was an ED₅₀=0.09 pmol/kg.

-14-

CLAIMS

1. A pharmaceutical composition for oral, parental, buccal, or rectal administration comprising an amount of (R)-5-(Methylaminosulfonylmethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole or a pharmaceutically acceptable salt thereof ranging from 0.1 μ g to less than 0.1 mg and a pharmaceutically acceptable carrier.
5
2. A pharmaceutical composition for oral, parental, buccal, or rectal administration comprising an amount of (R)-5-(Methylaminosulfonylmethyl)-3-(pyrrolidin-2-ylmethyl)-1H-indole or a pharmaceutically acceptable salt thereof ranging from 0.01 μ g to less than 0.1 mg and a pharmaceutically acceptable carrier.
10
3. A pharmaceutical composition for oral, parental, buccal, or rectal administration comprising an amount of (R)-5-(Methylaminosulfonylmethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole or a pharmaceutically acceptable salt thereof ranging from 0.1 μ g to 0.09 mg and a pharmaceutically acceptable carrier.
15
4. A pharmaceutical composition for oral, parental, buccal, or rectal administration comprising an amount of (R)-5-(Methylaminosulfonylmethyl)-3-(pyrrolidin-2-ylmethyl)-1H-indole or a pharmaceutically acceptable salt thereof ranging from 0.01 μ g to 0.09 mg and a pharmaceutically acceptable carrier.
20
5. A pharmaceutical composition for oral, parental, buccal, or rectal administration comprising an amount of (R)-5-(Methylaminosulfonylmethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole or a pharmaceutically acceptable salt thereof ranging from 0.5 μ g to 0.09 mg and a pharmaceutically acceptable carrier.
25
6. A pharmaceutical composition for oral, parental, buccal, or rectal administration comprising an amount of (R)-5-(Methylaminosulfonylmethyl)-3-(pyrrolidin-2-ylmethyl)-1H-indole or a pharmaceutically acceptable salt thereof
30
- 35

-15-

ranging from 0.05 μ g to 0.09 mg and a pharmaceutically acceptable carrier.

7. A pharmaceutical composition according to any one of claims 1 to 6, which is tablet, capsule, suppository, retention enema, or unit dose injection.

8. A pharmaceutical composition for aerosol administration comprising an amount of (R)-5-(methylaminosulfonylmethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole or (R)-5-(methylaminosulfonylmethyl)-3-(pyrrolidin-2-ylmethyl)-1H-indole, or a pharmaceutically acceptable salt thereof ranging from 0.01 μ g to less than 20 μ g per metered dose and a pharmaceutically acceptable carrier.

9. A pharmaceutical composition for aerosol administration comprising an amount of (R)-5-(methylaminosulfonylmethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole or (R)-5-(methylaminosulfonylmethyl)-3-(pyrrolidin-2-ylmethyl)-1H-indole, or a pharmaceutically acceptable salt thereof ranging from 0.01 μ g to 19 μ g per metered dose and a pharmaceutically acceptable carrier ingredient.

10. A pharmaceutical composition for aerosol administration comprising an amount of (R)-5-(methylaminosulfonylmethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole or (R)-5-(methylaminosulfonylmethyl)-3-(pyrrolidin-2-ylmethyl)-1H-indole, or a pharmaceutically acceptable salt thereof ranging from 0.05 μ g to 19 μ g per metered dose and a pharmaceutically acceptable carrier.

11. A method for treating a condition selected from hypertension, depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain and chronic paroxysmal hemicrania and headache associated with vascular disorders comprising administering to a mammal requiring such treatment an amount of (R)-5-(methylaminosulfonylmethyl)-3-(N-methylpyrrolidin-2-

-16-

ylmethyl)-1H-indole ranging from 0.1 μ g to less than 0.1 mg effective in treating such condition.

12. A method for treating a condition selected from hypertension, depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain and chronic paroxysmal hemicrania and headache associated with vascular disorders comprising administering to a mammal requiring such treatment an amount of (R)-5-(methylaminosulfonylmethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole ranging from 0.1 μ g to 0.09 mg effective in treating such condition.

13. A method for treating a condition selected from hypertension, depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain and chronic paroxysmal hemicrania and headache associated with vascular disorders comprising administering to a mammal requiring such treatment an amount of (R)-5-(methylaminosulfonylmethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole ranging from 0.5 μ g to 0.09 mg effective in treating such condition.

14. A method for treating disorders arising from deficient serotonergic neurotransmission comprising administering to a mammal requiring such treatment an amount of (R)-5-(methylaminosulfonylmethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole ranging from 0.1 μ g to less than 0.1 mg effective in treating such a disorder.

15. A method for treating disorders arising from deficient serotonergic neurotransmission comprising administering to a mammal requiring such treatment an amount of (R)-5-(methylaminosulfonylmethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole ranging from 0.1 μ g to 0.09 mg effective in treating such a disorder.

16. A method for treating disorders arising from deficient serotonergic neurotransmission comprising administering to a mammal requiring such treatment an amount of (R)-5-(methylaminosulfonylmethyl)-3-(N-methylpyrrolidin-

-17-

2-ylmethyl)-1H-indole ranging from 0.5 μ g to 0.09 mg effective in treating such a disorder.

17. A method for treating a condition selected from hypertension, depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain and chronic paroxysmal hemicrania and headache associated with vascular disorders comprising administering to a mammal requiring such treatment an amount of (R)-5-(methylaminosulfonylmethyl)-3-(pyrrolidin-2-ylmethyl)-1H-indole ranging from 0.01 μ g to less than 0.1 mg effective in treating such condition.

18. A method for treating a condition selected from hypertension, depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain and chronic paroxysmal hemicrania and headache associated with vascular disorders comprising administering to a mammal requiring such treatment an amount of (R)-5-(methylaminosulfonylmethyl)-3-(pyrrolidin-2-ylmethyl)-1H-indole ranging from 0.01 μ g to 0.09 mg effective in treating such condition.

19. A method for treating a condition selected from hypertension, depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain and chronic paroxysmal hemicrania and headache associated with vascular disorders comprising administering to a mammal requiring such treatment an amount of (R)-5-(methylaminosulfonylmethyl)-3-(pyrrolidin-2-ylmethyl)-1H-indole ranging from 0.05 μ g to less than 0.09 mg effective in treating such condition.

20. A method for treating disorders arising from deficient serotonergic neurotransmission comprising administering to a mammal requiring such treatment an amount of (R)-5-(methylaminosulfonylmethyl)-3-(pyrrolidin-2-ylmethyl)-1H-indole ranging from 0.01 μ g to less than 0.1 mg effective in treating such a disorder.

-18-

21. A method for treating disorders arising from deficient serotonergic neurotransmission comprising administering to a mammal requiring such treatment an amount of (R)-5-(methyaminosulfonylmethyl)-3-(pyrrolidin-2-ylmethyl)-1H-indole ranging from 0.01 μ g to 0.09 mg effective
5 in treating such a disorder.

22. A method for treating disorders arising from deficient serotonergic neurotransmission comprising administering to a mammal requiring such treatment an amount
10 of (R)-5-(methyaminosulfonylmethyl)-3-(pyrrolidin-2-ylmethyl)-1H-indole ranging from 0.05 μ g to 0.09 mg effective in treating such a disorder.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IB 94/00079

A. CLASSIFICATION OF SUBJECT MATTER
IPC 5 A61K31/40

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 5 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,92 06973 (PFIZER INC.) 30 April 1992 cited in the application see the whole document especially page 19, line 4-page 20, line 2 & page 65, lines 18-19 ---	1-22
P,X	BRAIN RESEARCH, vol.626, no.1-2, 29 October 1993 pages 303 - 304 LEE, W.S. ET AL 'CONFORMATIONALLY RESTRICTED SUMATRIPTAN ANALOGUES, CP-122,288 AND CP-122,638 EXHIBIT ENHANCED POTENCY AGAINST NEUROGENIC INFLAMMATION IN DURA MATER' cited in the application see the whole document -----	1-22

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

8 August 1994

Date of mailing of the international search report

16. 08. 94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Mair, J

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IB 94/00079

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 11-22 are directed towards a method of treatment of the human/animal body the search has been carried out and based on the alleged effects of the compositions.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.
PCT/IB 94/00079

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9206973	30-04-92	AU-B- 651637	28-07-94
		AU-A- 8950491	20-05-92
		BG-A- 97632	31-03-94
		CA-A- 2091562	16-04-92
		CN-A- 1062529	08-07-92
		DE-U- 9190141	15-07-93
		EP-A- 0592438	20-04-94
		HU-A- 64326	28-12-93

THIS PAGE BLANK (USPTO)